301075 多瑞医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.4342.4752.65513.23546.845
总资产报酬率 ROA (%)-0.3091.9132.34311.20827.655
投入资产回报率 ROIC (%)-0.3412.0742.44912.45439.273

边际利润分析
销售毛利率 (%)38.93168.55276.98188.60890.944
营业利润率 (%)-4.5586.6375.30013.86020.757
息税前利润/营业总收入 (%)-4.2815.2953.31613.85321.075
净利润/营业总收入 (%)-5.1835.1134.63412.43618.282

收益指标分析
经营活动净收益/利润总额(%)178.93316.70859.91786.99163.876
价值变动净收益/利润总额(%)-62.98825.6620.054-0.2680.000
营业外收支净额/利润总额(%)-3.2350.277-1.101-0.170-0.716

偿债能力分析
流动比率 (X)8.3175.0244.47811.6111.830
速动比率 (X)7.7214.7674.25211.4551.717
资产负债率 (%)25.39723.37016.1827.3750.351
带息债务/全部投入资本 (%)22.58119.27812.1962.96114.365
股东权益/带息债务 (%)340.466416.939719.0753,277.070596.129
股东权益/负债合计 (%)276.538308.101516.6751,262.815186.027
利息保障倍数 (X)-32.082-3.893-1.722836.48345.217

营运能力分析
应收账款周转天数 (天)110.34191.08884.25567.17969.452
存货周转天数 (天)75.412112.82583.04573.54487.230